ArticleAdvanced pharmaceutical bulletin2026
Development of AS1411 Aptamer-Targeted Solid Lipid Nanoparticles to Improve Anticancer Efficiency of Lawsone.
Article in Advanced pharmaceutical bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lawsone (LWS), a naphthoquinone dye known for its anticancer properties, faces challenges with aqueous solubility, which restricts its therapeutic use. Solid lipid nanoparticles (SLNs) are recognized for enhancing the bioavailability of poorly soluble drugs, supporting in targeted drug delivery and reducing toxicity to normal tissues. The purpose of this study was to develop chitosan-coated solid lipid nanoparticles that were loaded with lawsone and conjugated with the AS1411 aptamer (LWS-SLN-Chit-Apt) for evaluating the cytotoxic effects on mouse colon adenocarcinoma cells (C26). Methods: High-shear homogenization and ultrasound methods were used for producing the LWS-SLNs nanoparticles. Several considerations, including dynamic light scattering (DLS), differential scanning calorimetry (DSC), scanning electron microscopy (SEM), and Fourier-transform infrared spectroscopy (FTIR), were directed to characterize the properties of the nanoparticles. Next, the nanoparticles were coated with chitosan, then conjugated to AS1411 aptamer, which was confirmed with DLS and gel electrophoresis. Additionally, the encapsulation efficiency of LWS and its release profile were investigated. Cytotoxicity and cellular uptake were evaluated on C26 cells and Chinese hamster ovary (CHO) cells. Results: The LWS-SLNs and LWS-SLN-Chit-Apt formulations revealed particle sizes of 160±14.8 nm and 350±22.5 nm, with encapsulation efficiencies of 70.72±2.64% and 70.00±4.3%, respectively. Both formulations exhibited a sustained drug release profile over 120 hours. Targeted nanoparticles displayed higher cellular uptake and cytotoxicity in nucleolin-positive cells (C26 cells) compared to nucleolin-negative cells (CHO cells), with no substantial differences observed. Conclusion: These results illustrated that LWS-SLN-Chit-Apt could be considered as a great candidate for further studies and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.